Drug Trial Radar · NCT07449299
Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,458
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
Jun 2031
Study completion Nov 2031
Sponsor
- Lead sponsor
- University of UtahAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 16 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized controlled trial will test oral levonorgestrel + piroxicam vs. levonorgestrel + placebo for emergency contraception in a representative U.S. population that has higher pregnancy risk than in the prior study because of higher weights, different intercourse patterns, and different clinic accessibility. Data from this project will inform clinical practice in the U.S. and beyond for those desiring the most effective method of emergency contraception pills.
Conditions
- Emergency Contraception
- Contraception
- COX-2 Inhibitor
Interventions
Levonorgestrel 1.5 mg and Piroxicam 40 mgDrug
The study intervention is a combination of Levonorgestrel 1.5 mg and Piroxicam 40 mg for emergency contraception. Participants will be randomized 3:1 to this vs. Levonorgestrel 1.5 mg and placebo.
Oral LNG + PlaceboDrug
The study intervention is a combination of Levonorgestrel 1.5 mg and placebo for emergency contraception. Participants will be randomized 3:1 to Levonorgestrel 1.5 mg and Piroxicam vs. this option.
Primary outcomes
What the sponsor says the trial is designed to measure.
- EC efficacy between the two study groups measured by pregnancy status four weeks after EC use.Time frame: One month after consuming study drug
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.